Afimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.
|Articles|January 22, 2015
FDA Approves IL-17 Blocker Secukinumab for Plaque Psoriasis
Advertisement
The US Food and Drug Administration (FDA) has approved the interleukin 17A inhibitor secukinumab (Cosentyx) for adults with moderate to severe plaque psoriasis.
Cosentyx is administered as a subcutaneous injection and may be used in combination with phototherapy.
In reports at the American College of Rheumatology meeting last November, secukinumab showed
Advertisement
Related to this article
The 200-mg dose improved ACR20 response vs placebo at week 16 in biologic-naïve patients, while the 400-mg dose added no benefit.
An international IgG4ward! Foundation panel issued 28 treatment statements for IgG4-related diseases, with consensus reached on 22.
In 33 patients with myositis-associated ILD from FIBRONEER-ILD, nerandomilast numerically slowed FVC decline and lowered progression risk.
RESET-RA 24-month data show sustained clinical responses with vagus nerve stimulation in patients with treatment-experienced RA.
In a matched claims analysis, 94% of patients with PMR initiating sarilumab discontinued glucocorticoids by 12 months vs 78% initiating methotrexate.
Patients with relapsing GCA who stopped upadacitinib after year 1 flared sooner and needed far more glucocorticoids than new-onset patients.
In year 2 of SELECT-GCA, 6.0% of patients continuing upadacitinib flared vs 55.9% switched to placebo.
Advertisement
Advertisement
Trending on Rheumatology Live
1
Nipocalimab, Telitacicept, and the Sjögren’s Disease Pipeline
2
Dazodalibep Eases Sjögren’s Dryness via CD40L Blockade: Ghaith Noaiseh, MD
3
Dazodalibep Lowers Sjögren’s Disease Activity: Ghaith Noaiseh, MD
4
Selecting Sjögren’s Patients for Ianalumab and Weighing Safety
5